Growth & profitability
- Revenue has grown 12.1% per year over the past 5 years.
- Operating margin has expanded, at 8.0% in the latest year.
- Free cash flow has grown 59.2% per year over the past 5 years.
CSBR Financials CHAMPIONS ONCOLOGY, INC.
15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $57M | $5M | 50.1% | 8.0% | $7M | — | $10M |
| 2024 | $50M | -$7M | 41.4% | -14.7% | -$7M | — | $3M |
| 2023 | $54M | -$5M | 45.2% | -9.8% | $1M | — | $10M |
| 2022 | $49M | $548000 | 51.9% | 1.2% | $4M | — | $9M |
| 2021 | $41M | $362000 | 47.7% | 0.9% | -$5M | — | $5M |
| 2020 | $32M | -$2M | 47.1% | -6.0% | $685000 | — | $8M |
| 2019 | $27M | $128000 | 0.0% | 1.0% | $1M | — | $3M |
| 2018 | $20M | -$1M | 0.0% | -6.7% | -$2M | — | $856000 |
| 2017 | — | -$7M | — | — | -$4M | — | $3M |
| 2016 | — | -$10M | — | — | -$7M | — | $3M |
| 2015 | — | -$13M | — | — | -$10M | — | $9M |
| 2014 | — | -$7M | — | — | — | — | $6M |
| 2013 | — | -$6M | — | — | -$4M | — | $10M |
| 2012 | — | -$9M | — | — | -$6M | — | $5M |
| 2011 | — | -$4M | — | — | -$139000 | — | $10M |
RevenueNet income
GrossOperatingNet
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Jan '26 | $17M | -$279000 | 46.7% | -1.7% | -$1M | — | $7M |
| Oct '25 | $15M | $268000 | 51.7% | 1.2% | -$2M | — | $9M |
| Jul '25 | $14M | -$436000 | 42.9% | -3.8% | $554000 | — | $10M |
| Apr '25 | $12M | -$2M | 41.1% | -16.2% | $7M | — | $10M |
| Jan '25 | $17M | $4M | 61.2% | 26.4% | $448000 | — | $3M |
| Oct '24 | $13M | $728000 | 44.9% | 5.4% | -$377000 | — | $3M |
| Jul '24 | $14M | $1M | 49.7% | 9.5% | $311000 | — | $3M |
| Apr '24 | $14M | -$133000 | 48.2% | -1.9% | -$2M | — | $3M |
| Jan '24 | $12M | -$3M | 34.7% | -21.4% | -$1M | — | $4M |
| Oct '23 | $12M | -$2M | 42.8% | -16.9% | $510000 | — | $6M |
| Jul '23 | $13M | -$3M | 38.8% | -20.3% | -$5M | — | $5M |
| Apr '23 | $13M | -$3M | 43.9% | -19.3% | -$1M | — | $10M |
| Jan '23 | $13M | -$2M | 39.7% | -19.2% | $819000 | — | $12M |
| Oct '22 | $14M | -$16000 | 47.9% | 0.0% | $3M | — | $11M |
| Jul '22 | $14M | -$319000 | 48.7% | -2.1% | -$949000 | — | $8M |
| Apr '22 | $13M | -$344000 | 51.7% | -2.4% | $290000 | — | $9M |
| Jan '22 | $13M | $787000 | 51.4% | 6.3% | $4M | — | $9M |
| Oct '21 | $12M | $277000 | 52.4% | 2.2% | $662000 | — | $5M |
| Jul '21 | $11M | -$172000 | 52.0% | -1.6% | -$691000 | — | $4M |
| Apr '21 | $11M | -$673000 | 44.7% | -6.1% | -$3M | — | $5M |
Valuation over time
How the market has priced CSBR against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-earnings ratio has fallen from 104.2× (Mar '23) to 18.2× (Jun '26).
- The price-to-sales ratio has risen from 1.2× (Mar '23) to 1.5× (Jun '26).
P/E
P/S
Frequently asked questions
Is CSBR growing its revenue and profit?
Over the past 5 years, CHAMPIONS ONCOLOGY, INC.'s revenue has grown 12.1% per year. These are computed facts, not advice.
How much debt does CSBR have?
As of FY2025, CHAMPIONS ONCOLOGY, INC. reported — of total debt against $10M of cash.
What is CSBR's profit margin?
In FY2025, gross margin was 50.1%, operating margin 8.0%, and net margin 8.3%.
What is CSBR's P/E ratio?
As of Jun '26, CHAMPIONS ONCOLOGY, INC. traded at a price-to-earnings ratio of about 18.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.